Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Olaparib + Pembrolizumab for Breast Cancer
Recruiting1 awardPhase 2
Middletown, New Jersey
This trial will test the efficacy of combining two drugs, pembrolizumab and olaparib, given before surgery, to treat TNBC or HR+ HER2- breast cancers. The study drugs could potentially shrink the cancer, but they may also cause side effects. The goal of the trial is to see if the study drugs will shrink the cancer by a certain percentage compared with its current size, which may improve the outcome of surgery.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service